ICER weighs up billion-dollar question on remdesivir

4 May 2020
money_drugs_scales_large-1-

How much should a potentially effective drug for COVID-19 cost?

That is the question weighed up by the Institute for Clinical and Economic Review (ICER) after the US Food and Drug Administration gave emergency use approval to Gilead Sciences’ (Nasdaq: GILD) remdesivir.

The ICER has released the results of its initial analyses to inform public debate of pricing for remdesivir, and has come up with two alternative pricing paradigms for COVID-19 treatments.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical